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Précis 
Analysis of 52 eyes with high-risk retinoblastoma managed with post-enucleation adjuvant 
chemotherapy using vincristine sulfate, etoposide phosphate, and carboplatin showed no 
evidence of systemic metastasis in any case over a mean follow-up of 66 (12 to 202) months.  
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Abstract 
Purpose: To determine the efficacy of post-enucleation adjuvant chemotherapy with vincristine sulfate, 
etoposide phosphate and carboplatin (VEC) in the prevention of metastasis for patients with high-risk 
retinoblastoma. 
Methods: Retrospective, nonrandomized, interventional case series of 52 eyes in 51 patients 
with high-risk retinoblastoma consisting of tumor invasion into the anterior segment, posterior 
uvea 3 mm or greater, post-laminar optic nerve, or any combination of posterior uvea and 
optic nerve involvement. 
Results: Of 51 consecutive patients with high-risk retinoblastoma, there were 30 males (59%) and 21 
females (41%), with a median age of 28 months at diagnosis. All 52 eyes were classified as group E. 
The main histopathologic risk factors included anterior segment invasion (7 [13%]), isolated massive 
posterior uveal invasion of 3mm or greater (6 [12%]), isolated postlaminar optic nerve invasion (15 
[29%]), or any posterior uveal invasion with any optic nerve involvement (24 [46%]). There was 
additional invasion into the sclera (3 [6%]) and extrascleral structures including the orbit (1 [2%]). A 
single histopathologic high-risk factor was present in 32 eyes (62%), whereas 20 eyes (38%) 
manifested 2 or more high-risk characteristics. Based on previously published series, untreated high-
risk retinoblastoma carries at least a 24% risk for metastatic disease. In the present series, using 
vincristine sulfate, etoposide phosphate, and carboplatin in all cases, there was no metastasis during a 
mean follow-up of 66 months (median [range], 55 [12-202] months). 
Conclusion: Retinoblastoma with invasion into the postlaminar optic nerve and/or posterior 
uvea is at high risk for metastasis and death. In this study, post-enucleation chemotherapy using 
vincristine sulfate, etoposide phosphate, and carboplatin was effective in preventing metastasis in every 
case (100%). 
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Retinoblastoma (RB) is the most common primary malignant intraocular tumor in the 
world, and the second most common primary intraocular malignancy in the Western 
Hemisphere, after uveal melanoma. It is estimated that 7202 to 8102 new cases of RB are 
diagnosed worldwide each year.1 The mean age-adjusted incidence of RB in children aged 
birth to 4 years is 11.8 per million, with a 5-year survival of 96.5% in the United States of 
America.2,3 On the basis of the mortality data and birth rates in corresponding continents, it is 
estimated that 3001 to 3376 children die of RB annually, most deaths occurring in less 
developed areas, such as parts of Africa (death rate of 70%) and Asia (death rate of 42%).1 
Poor survival in these regions is due to late diagnosis, leading to advanced malignant 
neoplasms showing invasive features that are prone to micrometastatic disease.1,4,5  
In RB, there are histopathologic factors that have been identified from enucleated 
eyes predictive of the development of metastatic disease and related mortality.6-9 Patients 
demonstrating such risk factors are often given postenucleation adjuvant chemotherapy for 
protection from metastasis and improvement in survival.10  
There is some controversy regarding the exact definition of high-risk histopathologic 
features11,12 and further debate regarding the most effective chemotherapeutic protocol for 
treatment of such patients.13,14 In this retrospective, noncomparative study, we investigated 
the role of a single chemotherapeutic protocol using vincristine sulfate, etoposide phosphate, 
and carboplatin in the prevention of RB metastasis in high-risk cases following enucleation.   
 
Methods 
This study was a retrospective, non-randomized, non-comparative, interventional case series. 
Institutional review board approval was obtained. The medical records of all patients with RB managed 
with enucleation on the Ocular Oncology Service at Wills Eye Institute in Philadelphia from January 1, 
1994, through December 31, 2010, were reviewed. The histopathologic features of the enucleated 
specimen were reviewed. High-risk histopathologic features were defined as the presence of 1 or more 
of the following features: tumor invasion into the anterior segment, posterior uvea of 3 mm or greater, 
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postlaminar optic nerve involvement, or any posterior uveal invasion with any optic nerve 
involvement. (Figure 1). Optic nerve invasion was classified as prelaminar, at the lamina cribrosa, 
postlaminar, and/or to the site of transection. Additional invasion into the sclera and extrascleral 
structures including the orbit were recorded. Patients with high-risk RB who received post-enucleation 
adjuvant chemotherapy with vincristine sulfate, etoposide phosphate and carboplatin (VEC), and with a 
minimum follow-up of 1 year were included in this study. High-risk RB patients treated with 
chemotherapeutic agents other than VEC, and patients enrolled in Children’s Oncology Group study 
ARET-0332, were excluded. 
 The medical records were reviewed for clinical and histopathologic findings. The 
demographic data included age at diagnosis (months), sex and race. Genetic results (germline, somatic) 
for RB were recorded when available. The hereditary pattern (sporadic, familial) and prior local or 
systemic treatment for RB was noted. The presenting symptoms, duration of symptoms (days) and 
visual acuity were recorded. The tumor laterality (unilateral, bilateral), total number of tumors per eye, 
International Classification of Retinoblastoma, Reese-Ellsworth classification, intraocular pressure 
(millimeters of mercury Hg by Schiotz tonometry), and status of the anterior chamber, iris, ciliary 
body, optic nerve, choroid, and vitreous were noted. Each tumor was measured for greatest basal 
dimension (millimeters), thickness (millimeters), and proximity to the optic disc and foveola 
(millimeters). Clinical features of anterior chamber seeding, hyphema, iris neovascularization, vitreous 
seeding, vitreous hemorrhage, subretinal seeding, tumor calcification, retinal detachment, 
neovascularization of the optic disc, neovascularization elsewhere, optic disc edema, and choroidal 
invasion were noted. All findings were documented by large fundus drawings, fundus photography 
with RetCam camera (Massie Industries, Dublin, California), fluorescein angiography, and 
ultrasonography.  
The initial treatment and reason for enucleation were recorded. The eyes were sent for 
histopathologic assessment, and the findings were reviewed for high-risk features. Other 
histopathologic findings noted were growth pattern (exophytic, endophytic, combined exophytic-
endophytic), tumor location (quadrant), presence of necrosis and dystrophic calcification, depth and 
lateral extent of choroidal invasion (millimeters), depth of postlaminar optic nerve invasion 
(millimeters) and tumor differentiation.  
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In patients with high-risk RB, post-enucleation adjuvant therapy by intravenous VEC was 
administered. Dosage (Table 1), number of cycles, and complications of VEC systemic chemotherapy 
were recorded. After VEC chemotherapy, metastatic evaluation included history and physical 
examination, computed tomography and/or magnetic resonance imaging of the orbit and brain repeated 
at 6-month intervals until age 5 years. Systemic findings from the metastatic evaluation, duration of 
follow-up (months) and the final systemic outcome (alive without metastasis, alive with metastasis, 
alive with second malignant neoplasm, dead from metastasis, dead from second malignant neoplasm, 
or dead from other causes) were recorded. 
 
Results 
Of 406 eyes enucleated for RB during this period, 66 eyes (16.3%) had 1 or more high-risk 
histopathologic features predictive of systemic metastasis. Of these 66 eyes, 52 eyes (79%) of 51 
patients were treated with VEC with a minimum follow-up of 1 year and were included in this study. 
The demographic data are listed in Table 2.  
The clinical features at presentation are listed in Table 3. Five (10%) patients had a history of 
previous intraocular surgery, which included vitrectomy and sclera buckle (n=2), vitrectomy alone 
(n=2) and anterior chamber tap (n=1).  
The classification of each eye using Reese Ellsworth classification revealed 51 group Vb 
(98%) and 1 group Va (2%). According to the International Classification of Retinoblastoma, all 52 
eyes (100%) were group E.  
Enucleation was preceded by systemic chemotherapy in 4 patients (8%), external beam 
radiotherapy in 1 (2%), plaque radiotherapy in 1 (2%), and subconjunctival carboplatin in 1 (2%). The 
reason for enucleation included massive tumor involving 50% or more of the vitreous with no visual 
potential in 45 eyes (87%), recurrence after chemoreduction in 4 (8%), recurrence after external beam 
radiotherapy in 1 (2%), recurrence after plaque in 1 (2%), and necrotic tumor with orbital inflammation 
in 1 (2%).  
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The histopathologic features are listed in Table 4. All cases with scleral and/or extrascleral 
invasion also had additional postlaminar and/or massive choroidal invasion. High-risk features were 
noted in the right eye in 24 patients (47%), left eye in 26 (51%) and both eyes in 1 (2%). The optic 
nerve stump at enucleation was a mean length of 15 mm (median, 14 mm; range, 8-22 mm).  
All 51 patients received intravenous chemotherapy using VEC standard dose (Table 1). The 
mean number of VEC cycles per patient was 6 (median [range] 6 [4-6]). There were 4 patients (8%) 
who received 4 cycles of VEC, and the remaining patients received 6 cycles of VEC. The only 
chemotherapy-related complication was pneumonia in 1 (2%). There was no case of etoposide-related 
leukemia. One patient (2%) had extrascleral extension along with the high-risk feature of combined 
optic nerve and choroidal invasion, for which chemotherapy and additional orbital external beam 
radiotherapy was given after enucleation. 
All patients (100%) were followed for more than 1 year and the mean duration of follow-up 
after adjuvant chemotherapy was 66 months (median [range], 55 [12-202] months). Of 51 patients, 43 
(84%) had more than 2 years’ follow-up, 41 (80%) had more than 3 years’ follow-up, and 22 (43%) 
patients had more than 5 years’ follow-up. The incidence (95% confidence interval) of metastasis was 
0% [0 to 6%) at 1 year, 0% (0 to 7%) at 3 years, and 0% (0 to 14%) at 5 years. There was no second 
malignant neoplasm or death in any case. 
Discussion 
In nations with advanced medical care, the incidence of metastasis in children with RB is less 
than 10%.15 The risk for metastasis greatly increases with histopathologic evidence of high-risk 
features. In a study from our institution, Honavar and associates10 found that untreated patients with 
high-risk histopathologic features developed metastases in 24% of cases, often leading to death. This 
risk could be much greater in undeveloped nations where high-risk features are more extreme, with 
macroscopic rather than microscopic invasion. The use of postenucleation adjuvant chemotherapy has 
been recommended for patients with high-risk features on histopathologic analysis to eradicate 
presumed micrometastases before they are clinically manifest and to reduce ultimate death.10,13  
There is considerable controversy in the definition of risk factors for RB metastasis based on 
histopathologic features. There is also debate regarding the most effective treatment strategies for 
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affected patients. In previous studies, histopathologic risk factors for RB metastasis included anterior 
segment invasion, massive uveal invasion (defined as >2 mm), scleral infiltration, extrascleral invasion, 
postlaminar optic nerve invasion, and invasion to the site of surgical transection of the optic 
nerve.12,16,17  Following enucleation, the incidence of high-risk histopathologic features has varied from 
7% to 9% for anterior segment invasion,8,17 12% to 42% for choroidal invasion,5,7-9,17 8% to 12% for 
scleral invasion,5,8,9,17 2% to 20% for extrascleral invasion,5,8,9,17 6% to 28% for invasion of postlaminar 
optic nerve,5,6,8,9,17,18 1% to 38% for involvement of optic nerve to surgical transection.5,6,7,8,9,17,18 
 In a recent comprehensive report on histopathologic findings following enucleation in 297 
untreated eyes of RB, Eagle16 identified high-risk features in 55 eyes (18.5 %). In these 55 eyes, these 
features included massive (defined as >3mm) uveal invasion with no optic nerve invasion (8 [14.5%]), 
massive uveal invasion with prelaminar optic nerve invasion (7 [12.7%]), massive uveal invasion with 
postlaminar optic nerve invasion (10 [18.2%]), postlaminar optic nerve invasion with no uveal invasion 
(18 [32.7%]), postlaminar optic nerve invasion with nonmassive uveal invasion (3 [5.5%]), combined 
nonmassive uveal invasion without postlaminar optic nerve invasion (2 [3.6%]), and anterior segment 
involvement (8 [14.5%]). 
According to Chantada and associates,12 there are world disparities in risk definition and 
management of RB. On the basis of our previous experience, we believe that anterior segment 
invasion, massive posterior uveal invasion of 3 mm or greater, postlaminar optic nerve invasion, or a 
combination of any degree of posterior uveal and optic nerve invasion pose a risk; therefore, we 
include these 4 factors in our definition as high-risk. The significance of isolated anterior segment 
involvement remains debatable, but we have previously witnessed metastasis in such cases, so this was 
included as a factor.10 Some authors5,13 have suggested that anterior segment involvement and isolated 
choroidal invasion are not risk factors for metastasis. The other major source of variation is related to 
the definition of massive choroidal invasion.12 In a survey by the International Retinoblastoma Staging 
Working Group, composed of 58 members from 24 countries in 4 continents, at least 5 different criteria 
have been reported including full-thickness choroidal invasion with at least 1 cell adherent to the 
sclera, full invasion greater than 50% thickness of the choroid or more than 1 cluster, deep invasion 
greater than 50% of the thickness of the choroid, diffuse choroidal invasion of more than 3 clusters, and 
invasion greater than 3 mm in largest dimension or tumor noted on gross examination. For consensus in 
 11 
that group, the criterion for massive choroidal invasion was agreed to be maximum diameter (thickness 
or width) of tumor at 3 mm or greater.12 
A search for the most effective chemotherapy for RB has been underway since the 1950s.19-22 
Previous studies on adjuvant chemotherapy for high-risk RB have revealed several protocols including 
agents such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, etoposide, cisplatin, 
carboplatin, and cyclosporine.14,23 As shown in Table 5, postenucleation adjuvant chemotherapy 
regimens have varied over the years. The metastatic rate has ranged from 4% in a study of 26 cases in 
which vincristine sulfate and cyclophosphamide was used to 33% in a study of 24 cases in which 
vincristine sulfate, cyclophosphamide, and doxorubicin was used.26,27 Mustafa and associates30 
studied the effect of vincristine sulfate, doxorubicin, and cyclophosphamide in high-risk RB and found 
distant metastasis and subsequent death in 19% cases. They concluded that alternative 
chemotherapeutic agents should be considered for patients with such high-risk features. Uusitalo and 
associates31 studied 129 patients using variable regimens and concluded that chemoprophylaxis was 
beneficial in patients with tumor extending beyond the lamina cribrosa. Honavar and colleagues10 
conducted a retrospective, nonrandomized comparative study of 80 patients with high-risk RB, in 
which 58% of patients received adjuvant therapy and 42% did not receive adjuvant therapy for various 
reasons. A significant difference was found in the rate of metastasis between the group that had 
received adjuvant therapy (4%) and the group that had not (24%). The beneficial effect of adjuvant 
therapy was statistically significant in subgroups with massive choroidal infiltration and/or postlaminar 
optic nerve invasion.  
In our study, we used a standard multi-agent chemotherapeutic protocol of VEC in every case 
of high-risk RB. With this regimen, there was no case of metastasis or death during the mean follow-up 
period of more than 5 years. These same chemotherapeutic agents have proven effective as neoadjuvant 
chemotherapy.33 On the basis of our results, VEC is impressively effective for postenucleation high-
risk RB in the prevention of systemic metastases, thereby improving survival. 
 . 
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Figure 1:  
Successful management of high-risk retinoblastoma using vincristine, etoposide, and carboplatin, 
illustrating the various degrees of invasive malignancy. 
A,B,C. Anterior chamber invasion of retinoblastoma with pseudohypopyon (A) and iris, ciliary body, 
and trabecular meshwork invasion on 10x magnification (B) and 40x magnification (C). 
D, E, F. Tumor invasion into the optic nerve in the pre-laminar (D), laminar (E), and post-laminar (F) 
region. 
G, H, I. Solitary massive choroidal invasion of 16mm (G), combined massive choroidal and optic nerve 
invasion (H), and massive choroidal invasion with extrascleral extension (I). 
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Table 1: Postenucleation Adjuvant Chemotherapy in the Treatment of High-Risk Retinoblastoma: 
Chemotherapeutic regimena 
 
Chemotherapeutic Regimen 
Day Vincristine sulfate, 
0.05mg/kg 
Etoposide phosphate, 5 
mg/kg 
Carboplatin, 18.6 
mg/kg 
0 x x x 
1 … x … 
a The regimen was planned for 4 to 6 cycles.  
 
 
 
 
 
 
 
 
 19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Demographic Features of 51 Patients Receiving Treatment for High-Risk Retinoblastomaa  
 
Demographic feature Value 
Age (months)  
 20 
 
aData are given as number (percentage) of patients unless otherwise specified. 
bGenetic testing was available in only 14 of 51 patients. 
 
 
 
Mean (median [range]) 42 (28 [4 to 368]) 
     < 12 months 9 (18) 
     > 12 months 42 (82) 
Gender  
     Male 30 (59) 
        Female 21 (41) 
Race  
     Caucasian 35 (69) 
African-American 6 (12) 
     Hispanic 10 (20) 
Heredity   
     Sporadic 49 (96) 
     Familial 2 (4) 
Genetic testingb  
     Somatic 9/14 (64) 
     Germline 5/14 (36) 
Laterality  
     Unilateral 32 (63) 
     Bilateral 19 (37) 
Eye with high-risk features  
     Right 24 (47) 
     Left 26 (51) 
     Both 1 (2) 
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Table 3. Clinical Features at Presentation of 51 Patients Receiving Treatment for High-Risk 
Retinoblastoma 
 
Clinical feature Value 
Presenting symptoma  
     Leucocoria 33 (63) 
     Strabismus 10 (19) 
Decreased vision 6 (12) 
Blind painful eye 3 (6) 
Red eye 2 (4) 
Heterochromia  2 (4) 
Duration of symptoms, mean (median [range]), days 114 (38 [0 to 730]) 
History of previous intraocular surgery  
 22 
Anterior chamber tap 1 (2) 
Vitrectomy with or without scleral buckle 4 (8) 
Visual acuity  
Fix and follow 15 (29) 
No fix or follow 37 (71) 
Intraocular pressure, mean (median [range]), mm Hg 22 (21 [<4 to 50) 
Clinical signs  
Secondary Glaucoma 23 (44) 
Anterior chamber seeding 16 (31) 
Neovascularization iris 22 (42) 
Hyphema 4 (8) 
Vitreous seeds 37 (71) 
Subretinal seeds 12 (23) 
Subretinal fluid 16 (31) 
     Vitreous hemorrhage 8 (15) 
Basal diameter of largest tumor, mean (median [range]), mm 20 (21 [10 to 24]) 
Ultrasonographic thickness, mean (median [range]), mm 12 (13 [3 to 18]) 
aTotal may not equal 100% because 4 patients had more than 1 presenting complaint. 
 
 
 
 
 
 
 
 
 
 23 
 
 
 
 
 
 
Table 4. Histopathologic Features of 51 Patients Receiving Treatment for High-Risk Retinoblastoma 
 
Histopathologic feature Number (%) of patients 
Growth pattern  
Endophytic 12 (23) 
Exophytic 6 (12) 
Both endophytic and exophytic 27 (52) 
Diffuse infiltrating 7 (13) 
Tumor differentiation  
Well differentiated 5 (10) 
Moderately differentiated 0 
Poorly differentiated 43 (83) 
     Undifferentiated 4 (8) 
Necrosis 45 (87) 
Dystrophic calcification 48 (92) 
Main histopathologic high-risk features   
Anterior segment invasiona 7 (13) 
Isolated posterior uveal invasion  >3mm 6 (12) 
Isolated postlaminar optic nerve  invasionb 15 (29) 
Any posterior uveal and optic nerve invasion 24 (46) 
Total histopathologic high-risk features  
 24 
Anterior segment 7 (13) 
MUI with no ONI 6 (12) 
MUI with non-postlaminar ONI 4 (8) 
Combined MUI and postlaminar    ONI 3 (6) 
Postlaminar ONI and no UI 15 (29) 
Postlaminar ONI and nonmassive UI 2 (4) 
     Combined nonmassive UI and non-postlaminar 
ONI 15 (29) 
Other features  
Iris infiltration 16 (31) 
Ciliary body infiltration 12 (23) 
Prelaminar optic nerve invasion 6 (12) 
Laminar optic nerve invasion 6 (12) 
Scleral infiltration 3 (6) 
Extrascleral infiltration 1 (2) 
Abbreviations: MUI, massive posterior uveal invasion; ONI, optic nerve invasion; UI, posterior uveal 
invasion. 
aAll patients with anterior chamber seeding had iris and/or ciliary body infiltration. 
bOne patient had invasion up to optic nerve surgical transection. 
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Table 5: The Role of Adjuvant Chemotherapy in Preventing Metastasis in High-Risk Retinoblastoma: 
Published Literaturea 
 
Source Chemotherapeutic 
Drugs Used 
No. of 
Patients 
Metastasis, No. (%) of 
Patients 
Howarth et al,29 1980 V, Cy 14 1 (7%) 
Wolff et al,30 1981 V, Cy 41 6 (12%) 
Keith et al,24 1989 V, Cy 26 1 (4%) 
Zelter et al,25 1991 V, D, Cy 24 8 (33%) 
Khelfaoui et al,9 1996 Variable** 75 4 (6%) 
Schvartzman et al,31 1996 V, D, Cy 29 4 (14%) 
Namouni et al,32 1997 V, Cy, C 6 1 (17%) 
Mustafa et al,26 1999 V, D, Cy 27 5 (19%) 
Uusitalo et al,27 2001 Variable** 11 1 (9%) 
Honavar et al,10 2002 V, D, Cy or V, E, C 46 2 (4%) 
Chantada et al,13 2004 V, D, Cy or V, I, Cy 24 4 (17%) 
Cuenca et al,33 2009 Variable** 32 6 (19%) 
Present study, 2010 V, E, C 52 0 (0%) 
 
Abbreviations: C, Carboplatin; Cy, cyclophosphamide; D, doxorubicin hydrochloride; E, etoposide; I, 
Idarubicin hydrochloride; V, Vincristine sulfate.  
aThe number of patients and overall results in some of the studies may be different from the data 
compiled in the table because only relevant and comparable data are tabulated.  
bMore than 2 regimens were used. 
 
 
